4D Molecular Therapeutics Reports Positive Interim Data From Phase 2b Trial For Wet AMD

(RTTNews) – 4D Molecular Therapeutics (FDMT) announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population. Additional data w

Source link